PROGRAM CHAIRS
Joel M. Gelfand, MD, MSCE, FAAD
James J. Leyden Professor of Dermatology and of Epidemiology
Vice Chair of Clinical Research (Dermatology)
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania
Philadelphia, PA
April W. Armstrong, MD, MPH
Professor and Chief of Dermatology
University of California Los Angeles
Los Angeles, CA
PROGRAM OVERVIEW
The goal of this program is to provide practicing clinicians with evidence-based strategies to ensure patients who are eligible for systemic therapy are appropriately evaluated and treated to achieve higher levels of skin clearance, optimize patient outcomes, and improve quality of life. This will enable clinicians to develop patient specific treatment plans that promote long-term outcomes of improved skin clearance and quality of life based on each individual’s unique clinical presentation.
TARGET AUDIENCE
This educational activity is intended for dermatologists and dermatology nurse practitioners and physician assistants involved in the care of patients with psoriasis.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the evidence-based recommendations for disease severity to appropriately select effective, systemic therapies
- Identify the impact on quality of life associated with special area involvement plaque psoriasis
- Construct patient-centered treatment plans using systemic therapies based on patient candidacy to maximize outcomes and improve quality of life
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Joel Gelfand, MD, MSCE, FAAD | Served as a consultant for AbbVie, Inc., Artax (DSMB), Bristol Myers Squibb, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies) GSK, Inmagene (DSMB), Lilly, Leo, Moonlake (DSMB), Janssen Biologics, Novartis Corp, UCB (DSMB), Neuroderm (DSMB), Oruka, Inc, and Veolia North America receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Amgen, Bristol Myers Squibb, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly pharmaceutical sponsors. Dr Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology, is Chief Medical Editor for Healio Dermatology (receiving honoraria) and is a member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society, receiving no honoraria. |
| April W. Armstrong, MD, MPH | Served as a consultant for AbbVie, Inc.; ASLAN; Almirall; Amgen; Arcutis; Beiersdorf; Bristol Myers Squibb; Dermavant; Eli Lilly; Janssen; LEO Pharma; Mindera; Novartis; Organon & Co; Sanofi; Sun Pharma; Takeda;
Ventyx Biosciences. Served on the speaker’s bureau for AbbVie, Inc.; Amgen; Bristol Myers Squibb; Galderma; Janssen; Mindera; Organon & Co; Sanofi; Takeda Received research funding from AbbVie, Inc.; ASLAN; Bristol Myers Squibb; Dermavant Sciences; Dermira; Eli Lilly; Galderma; Incyte; Janssen; Leo Pharma; Meiji Seika Pharma Co; Modernizing Medicine; Nimbus Therapeautics; Novartis; Ortho Dermatologics; Pfizer; Sanfoi Genzyme; UCB; Ventyx Biosciences Served on the Data Safety Monitoring Board for Boehringer Ingelheim; Parexel |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Chris Drury, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, MS, CMP, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: February 14, 2025
EXPIRATION DATE: February 14, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
